Abstract: The disclosure relates to methods of treating melanoma with kinase inhibitors. Methods of treating melanoma harboring wild-type or mutant BRAF with SU11652 are provided.
Type:
Application
Filed:
July 2, 2021
Publication date:
November 9, 2023
Applicant:
THE BOARD OF REGENTS OF THE UNVERSITY OF TEXAS SYSTEM
Abstract: In some embodiments, the present invention provides compositions that comprise: (1) a biodegradable polymer matrix; and (2) at least one biodegradable reinforcing particle that is dispersed in the matrix. In some embodiments, the biodegradable reinforcing particle is selected from the group consisting of porous oxide particles and porous semiconductor particles. In additional embodiments, the compositions of the present invention further comprise a (3) porogen particle that is also dispersed in the matrix. In further embodiments, the compositions of the present invention are also associated with one or more active agents. In various embodiments, the active agents are associated with the biodegradable polymer matrix, the biodegradable reinforcing particle, and/or the porogen particle. In various embodiments, the compositions of the present invention may be utilized as scaffolds, such as scaffolds for treating bone defects.
Type:
Application
Filed:
March 24, 2011
Publication date:
July 18, 2013
Applicant:
Board of Regents of the Unversity of Texas System
Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a SCAP gene (Human SCAP gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of a SCAP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Human SCAP expression and the expression of a SCAP gene using the pharmaceutical composition; and methods for inhibiting the expression of a SCAP gene in a cell.
Type:
Grant
Filed:
March 29, 2010
Date of Patent:
April 5, 2011
Assignees:
Alnylam Pharmaceuticals, Inc., Board of Regents, the Unversity of Texas System
Inventors:
Juergen Soutschek, Pamela Tan, Jay D. Horton, Michael S. Brown, Joseph L. Goldstein, Young-Ah Moon